Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chart: FDA’s Warning Letters Released the Weeks of March 22 & 29

This article was originally published in The Gray Sheet

Executive Summary

FDA's Warning Letters Released the Weeks of March 22 & 29

You may also be interested in...



Mylan Makes Decision On Potential First Botox Biosimilar

Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.

Mylan Pulls Generic Gilenya Application Over Study Concerns

Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.

Vindevogel’s Vision Healthcare Secures Avista Backing For US Entry

New York's Avista Capital Partners has taken a 50% stake in Belgian consumer health player Vision Healthcare, which has its sights set on the US market.

UsernamePublicRestriction

Register

SC142271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel